Ads
related to: asthma clinical guidelines- Eosinophil Diseases
Learn About A Treatment For
Multiple Eosinophil-Driven Diseases
- Eosinophilic Asthma Info
Read About A Treatment For Severe
Eosinophilic Asthma To Learn More.
- Dosing & Administration
View Dosing & Administration Info
For A Severe Asthma Medication.
- Clinical Trial Data
View Clinical Trial Data For A
Severe Eosinophilic Asthma Med.
- Treatment Admin Options
Uncover An SEA Treatment That
May Fit Your Patient's Schedule.
- Right For Your Patients?
Patient Profiles & Data Are Ready.
See If This SEA Tx Is A Good Fit.
- Eosinophil Diseases
Search results
Results From The WOW.Com Content Network
Anti-asthmatic agents, also known as anti-asthma drugs, refer to drugs that can aid in airway smooth muscle dilation to allow normal breathing during an asthma attack or reduce inflammation on the airway to decrease airway resistance for asthmatic patients, or both. The goal of asthmatic agents is to reduce asthma exacerbation frequencies and ...
The European Academy of Allergy and Clinical Immunology (EAACI) is a non-profit organisation for European clinicians, researchers and allied health professionals in the field of allergy and clinical immunology, covering asthma, rhinitis, eczema and occupational allergy, food and drug allergy, severe anaphylactic reactions, autoimmune disorders, and immunodeficiencies.
Asthma phenotyping and endotyping has emerged as a novel approach to asthma classification inspired by precision medicine which separates the clinical presentations of asthma, or asthma phenotypes, from their underlying causes, or asthma endotypes. The best-supported endotypic distinction is the type 2-high/type 2-low distinction.
GINA conducts continuous review of scientific publications on asthma and is a leader in disseminating information about the care of patients with asthma. [2] GINA publishes resources such as evidence-based guidelines for asthma management, and runs special events such as World Asthma Day. GINA's guidelines, revised each year, are used by ...
Acute severe asthma, also known as status asthmaticus, is an acute exacerbation of asthma that does not respond to standard treatments of bronchodilators (inhalers) and corticosteroids. [2] Asthma is caused by multiple genes , some having protective effect, with each gene having its own tendency to be influenced by the environment although a ...
Following new clinical safety trials, the FDA issued updated guidance on 20 December 2017, that there is no significant increased risk of serious asthma outcomes with LABAs when used together with inhaled corticosteroids. [25]
Ads
related to: asthma clinical guidelines